keyword
https://read.qxmd.com/read/38474161/timosaponin-a3-induces-anti-obesity-and-anti-diabetic-effects-in-vitro-and-in-vivo
#21
JOURNAL ARTICLE
Ji-Hyuk Park, Wona Jee, So-Mi Park, Ye-Rin Park, Seok Woo Kim, Hanbit Bae, Won-Suk Chung, Jae-Heung Cho, Hyungsuk Kim, Mi-Yeon Song, Hyeung-Jin Jang
Obesity is a serious global health challenge, closely associated with numerous chronic conditions including type 2 diabetes. Anemarrhena asphodeloides Bunge (AA) known as Jimo has been used to address conditions associated with pathogenic heat such as wasting-thirst in Korean Medicine. Timosaponin A3 (TA3), a natural compound extracted from AA, has demonstrated potential therapeutic effects in various disease models. However, its effects on diabetes and obesity remain largely unexplored. We investigated the anti-obesity and anti-diabetic properties of TA3 using in vitro and in vivo models...
March 2, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38472647/animal-studies-on-glucagon-like-peptide-1-receptor-agonists-and-related-polyagonists-in-nonalcoholic-fatty-liver-disease
#22
REVIEW
Chara Tsiampali, Ilias D Vachliotis, Antonis Goulas, Stergios A Polyzos
Nonalcoholic fatty liver disease (NAFLD) is a prevalent metabolic liver disease closely associated with the epidemics of obesity and type 2 diabetes mellitus (T2DM), but without licensed pharmacological treatment to date. As glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are approved anti-diabetic and anti-obesity medications, they were also considered a potential therapeutic option for NAFLD. Preclinical studies suggest that GLP-1RAs have a beneficial effect on major NAFLD histological outcomes, i...
March 12, 2024: Hormones: International Journal of Endocrinology and Metabolism
https://read.qxmd.com/read/38472626/expert-opinion-on-current-trends-in-the-use-of-insulin-in-the-management-of-people-with-type-2-diabetes-from-the-south-eastern-european-region-and-israel
#23
REVIEW
Adam G Tabak, Peter Kempler, Cristian Guja, Roy Eldor, Martin Haluzik, Tomasz Klupa, Nikolaos Papanas, Anca Pantea Stoian, Boris Mankovsky
Despite the availability of various antihyperglycaemic therapies and comprehensive guidelines, glycaemic control in diabetes management has not improved significantly during the last decade in the real-world clinical setting. Treatment inertia arising from a complex interplay among patient-, clinician- and healthcare-system-related factors is the prime reason for this suboptimal glycaemic control. Also, the key factor leading to inadequate glycaemic levels remains limited communication between healthcare professionals (HCPs) and people with type 2 diabetes (PwT2D)...
March 12, 2024: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://read.qxmd.com/read/38472620/renal-effects-of-glp-1-receptor-agonists-and-tirzepatide-in-individuals-with-type-2-diabetes-seeds-of-a-promising-future
#24
REVIEW
Irene Caruso, Francesco Giorgino
PURPOSE: Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes (T2D), and CKD-related disability and mortality are increasing despite the recent advances in diabetes management. The dual GIP/GLP-1 receptor agonist tirzepatide is among the furthest developed multi-agonists for diabetes care and has so far displayed promising nephroprotective effects. This review aims to summarize the evidence regarding the nephroprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RA) and tirzepatide and the putative mechanisms underlying the favorable renal profile of tirzepatide...
March 12, 2024: Endocrine
https://read.qxmd.com/read/38471612/chitosan-and-sodium-alginate-nanocarrier-system-controlling-the-release-of-rapeseed-derived-peptides-and-improving-their-therapeutic-efficiency-of-anti-diabetes
#25
JOURNAL ARTICLE
E-Qianqian Wang, Xinran Dong, Erick Damián Castañeda-Reyes, Ying Wu, Siling Zhang, Zeyu Wu, Zhaoming Wang, Lei Dai, Baocai Xu, Feiran Xu
Rapeseed-derived peptides (RPPs) can maintain the homeostasis of human blood glucose by inhibiting Dipeptidyl Peptidase-IV (DPP-IV) and activating the calcium-sensing receptor (CaSR). However, these peptides are susceptible to hydrolysis in the gastrointestinal tract. To enhance the therapeutic potential of these peptides, we developed a chitosan/sodium alginate-based nanocarrier to encapsulate two RPP variants, rapeseed-derived cruciferin peptide (RCPP) and rapeseed-derived napin peptide (RNPP). A convenient three-channel device was employed to prepare chitosan (CS)/sodium alginate (ALG)-RPPs nanoparticles (CS/ALG-RPPs) at a ratio of 1:3:1 for CS, ALG, and RPPs...
March 10, 2024: International Journal of Biological Macromolecules
https://read.qxmd.com/read/38471012/gut-microbiota-tryptophan-metabolism-glp-1-axis-participates-in-%C3%AE-cell-regeneration-induced-by-dapagliflozin
#26
JOURNAL ARTICLE
Yafei Jiang, Jin Yang, Li Xia, Tianjiao Wei, Xiaona Cui, Dandan Wang, Zirun Jin, Xiafang Lin, Fei Li, Kun Yang, Shan Lang, Ye Liu, Jing Hang, Zhe Zhang, Tianpei Hong, Rui Wei
Sodium-glucose co-transporter 2 (SGLT2) inhibitor, an efficacious anti-diabetic agent, which has cardiovascular and renal benefits, can promote pancreatic β-cell regeneration in type 2 diabetic mice. However, the underlying mechanism remains unclear. In this study, we aimed to use multi-omics to identify the mediators involved in β-cell regeneration induced by dapagliflozin. We showed that dapagliflozin lowered blood glucose level, upregulated plasma insulin level, and increased islet area in db/db mice...
March 12, 2024: Diabetes
https://read.qxmd.com/read/38470137/challenges-with-a-glucagon-like-peptide-1-glp-1-agonist-initiation-a-case-series-of-semaglutide-overdose-administration-errors
#27
JOURNAL ARTICLE
Brian G Wiener, Marlis Gnirke, Susi Vassallo, Silas W Smith, Mark K Su
BACKGROUND: Prescriptions of semaglutide, a glucagon-like peptide-1 receptor agonist administered weekly for Type 2 diabetes mellitus and obesity, are increasing. Adverse effects from semaglutide overdose are poorly described. We report adverse effects from three unintentional semaglutide overdoses upon initiation. CASE REPORTS: Case 1 : A 53-year-old man unintentionally injected semaglutide 2 mg instead of the recommended 0.1 mg. Case 2 : A 45-year-old woman unintentionally injected semaglutide 2...
March 12, 2024: Clinical Toxicology
https://read.qxmd.com/read/38469598/the-association-between-previous-use-of-anti-obesity-medication-and-semaglutide-weight-loss-outcomes
#28
JOURNAL ARTICLE
Wissam Ghusn, Sima Fansa, Diego Anazco, Elif Tama, Lizeth Cifuentes, Khushboo Gala, Alan De La Rosa, Daniel Sacoto, Alejandro Campos, Fauzi Feris, Daniela Hurtado, Andres Acosta
AIMS: To compare weight loss outcomes between patients starting semaglutide who had previously been on another anti-obesity medication (AOM) compared to those who were AOM-naïve. MATERIALS AND METHODS: We performed a retrospective study in patients with overweight or obesity taking semaglutide for weight loss for a duration of 3 to 12 months. Our primary endpoint was assessment of percentage of total body weight loss (TBWL) in patients who started semaglutide as their first AOM (AOM-naïve) compared to those who started semaglutide and had previously taken another AOM (non-AOM-naïve)...
March 12, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38468545/a-new-trivalent-recombinant-protein-for-type-2-diabetes-mellitus-with-oral-delivery-potential-design-expression-and-experimental-validation
#29
JOURNAL ARTICLE
Maryam Ehsasatvatan, Bahram Baghban Kohnehrouz
Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly used in clinical practice for the management of type 2 diabetes mellitus. However, the extremely short half-life of GLP-1 and the need for subcutaneous administration limit its clinical application. Thus, half-life extension and alternative delivery methods are highly desired. DARPin domains with high affinity for human serum albumin (HSA) have been selected for the half-life extension of therapeutic peptides and proteins. In the present study, novel trivalent fusion proteins as long-acting GLP-1 receptor agonists with potential for oral delivery were computationally engineered by incorporating a protease-resistant modified GLP-1, an anti-human serum albumin DARPin, and an approved cell-penetrating peptide (Penetratin, Tat, and Polyarginine) linked either by rigid or flexible linkers...
March 11, 2024: Journal of Biomolecular Structure & Dynamics
https://read.qxmd.com/read/38468245/underlying-mechanisms-and-cardioprotective-effects-of-sglt2i-and-glp-1ra-insights-from-cardiovascular-magnetic-resonance
#30
REVIEW
Angelica Cersosimo, Nadia Salerno, Jolanda Sabatino, Alessandra Scatteia, Giandomenico Bisaccia, Salvatore De Rosa, Santo Dellegrottaglie, Chiara Bucciarelli-Ducci, Daniele Torella, Isabella Leo
Originally designed as anti-hyperglycemic drugs, Glucagon-Like Peptide-1 receptor agonists (GLP-1Ra) and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated protective cardiovascular effects, with significant impact on cardiovascular morbidity and mortality. Despite several mechanisms have been proposed, the exact pathophysiology behind these effects is not yet fully understood. Cardiovascular imaging is key for the evaluation of diabetic patients, with an established role from the identification of early subclinical changes to long-term follow up and prognostic assessment...
March 11, 2024: Cardiovascular Diabetology
https://read.qxmd.com/read/38466894/sglt2-inhibitors-vs-glp-1-receptor-agonists-and-clinical-outcomes-in-patients-with-diabetes-with-without-atrial-fibrillation
#31
JOURNAL ARTICLE
Yi-Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, Hsin-Fu Lee, Pei-Ru Li, Yung-Hsin Yeh, Chi-Tai Kuo, Lai-Chu See, Gregory Y H Lip
CONTEXT: The coexistence of diabetes mellitus and atrial fibrillation (AF) is associated with substantial risks of adverse cardiovascular events. OBJECTIVE: The relevant outcomes associated with the use of sodium-glucose cotransporter-2 inhibitor (SGLT2i) versus glucagon-like peptide-1 receptor agonists (GLP-1RA) among patients with type 2 diabetes (T2D) with/without concomitant AF remained unknown. METHODS: In this nationwide retrospective cohort study from Taiwan National Health Insurance Research Database, there were 344,392 and 31,351 patients with T2D without AF, and 11,462 and 816 T2D patients with AF treated with SGLT2i and GLP-1RA from May 1, 2016, to December 31, 2019...
March 11, 2024: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/38465973/engineering-of-a-biologically-active-glycosylated-glucagon-like-peptide-1-analogue
#32
JOURNAL ARTICLE
Chaitra Chandrashekar, Feng Lin, Yuji Nishiuchi, Sam F Mohammed, Barbara F White, Yanni Arsenakis, Elita Yuliantie, Peishen Zhao, Sam van Dun, Anna Koijen, Yasuhiro Kajihara, Denise Wootten, Garron T Dodd, Leendert J van den Bos, John D Wade, Mohammed Akhter Hossain
Glucagon-like peptide receptor (GLP-1R) agonists (e.g., semaglutide, liraglutide, etc.) are efficient treatment options for people with type 2 diabetes and obesity. The manufacturing method to produce semaglutide, a blockbuster GLP-1 drug on the market, involves multistep synthesis. The large peptide has a hydrophobic fatty acid side chain that makes it sparingly soluble, and its handling, purification, and large-scale production difficult. The growing demand for semaglutide that the manufacturer is not capable of addressing immediately triggered a worldwide shortage...
March 11, 2024: Journal of Medicinal Chemistry
https://read.qxmd.com/read/38465586/should-we-stop-glucagon-like-peptide-1-receptor-agonists-before-surgical-or-endoscopic-procedures-balancing-limited-evidence-with-clinical-judgment
#33
JOURNAL ARTICLE
Guillermo Umpierrez, Francisco J Pasquel, Elizabeth Duggan, Rodolfo J Galindo
The American Society of Anesthesiologists (ASA) Task Force recently recommended discontinuing glucagon-like peptide-1 receptor agonist (GLP-1 RA) agents before surgery because of the potential risk of pulmonary aspiration. However, there is limited scientific evidence to support this recommendation, and holding GLP-1 RA treatment may worsen glycemic control in patients with diabetes. As we await further safety data to manage GLP-1 RA in the perioperative period, we suggest an alternative multidisciplinary approach to manage patients undergoing elective surgery...
March 11, 2024: Journal of Diabetes Science and Technology
https://read.qxmd.com/read/38465107/factors-influencing-the-choice-of-glucose-lowering-medications-among-physicians-treating-patients-with-type-2-diabetes
#34
JOURNAL ARTICLE
Mohammed E AlSofiani, Danah Z AlHalees, Joud A Aljebreen, Joud A Abu Dahesh, Ghada S Bamogaddam, Ghaida M AlBraithen, Anwar Jammah
Background The factors considered by physicians when prescribing a glucose-lowering agent to patients with type 2 diabetes (T2D) in real-world settings are not necessarily consistent with those recommended by clinical practice guidelines. Here, we identify the major factors that drive physicians' selection of glucose-lowering agents in the real world and how these factors may differ by physician's specialty.  Methods A web-based survey was conducted among 135 physicians who manage patients with T2D in Saudi Arabia...
February 2024: Curēus
https://read.qxmd.com/read/38464718/evolving-role-of-semaglutide-in-nafld-in-combination-weekly-and-oral-administration
#35
REVIEW
Evgenia Koureta, Evangelos Cholongitas
Non alcoholic fatty disease (NAFLD) is the most common chronic liver disease that is managed in the liver departments. It seems that the prevalence of the disease is rising worldwide and as it has the same pathogenetic pathways with metabolic syndrome, treatments that target components of the metabolic syndrome seem promising for the therapy of NAFLD as well. In this review we discuss the evolving role of semaglutide, which is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that has been already approved for the treatment of type II diabetes mellitus (T2DM) and obesity...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38464707/pulse-of-progress-a-systematic-review-of-glucagon-like-peptide-1-receptor-agonists-in-cardiovascular-health
#36
REVIEW
Michael Sabina, M Mrhaf Alsamman
According to the World Health Organization (WHO), the prevalence of type 2 diabetes mellitus (T2DM) and obesity has increased globally over the past 50 years, affecting over 500 million adults worldwide in 2023. A novel class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a beacon of hope in treating the pandemic of diabetes and obesity. This analysis' objective was to draw comparisons of how these medications reduce cardiovascular outcomes. The review revealed unique differences in GLP-1s, highlighting some of their strengths and weaknesses and which populations they can cater to preferentially...
February 2024: Cardiology Research
https://read.qxmd.com/read/38464377/glucagon-like-peptide-1-receptor-agonists-as-a-possible-intervention-to-delay-the-onset-of-type-1-diabetes-a-new-horizon
#37
EDITORIAL
Mahmoud Nassar, Ajay Chaudhuri, Husam Ghanim, Paresh Dandona
Type 1 diabetes (T1D) is a chronic autoimmune condition that destroys insulin-producing beta cells in the pancreas, leading to insulin deficiency and hyper-glycemia. The management of T1D primarily focuses on exogenous insulin replacement to control blood glucose levels. However, this approach does not address the underlying autoimmune process or prevent the progressive loss of beta cells. Recent research has explored the potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as a novel intervention to modify the disease course and delay the onset of T1D...
February 15, 2024: World Journal of Diabetes
https://read.qxmd.com/read/38463003/potent-incretin-based-therapy-for-obesity-a-systematic-review-and-meta-analysis-of-the-efficacy-of-semaglutide-and-tirzepatide-on-body-weight-and-waist-circumference-and-safety
#38
REVIEW
Alberte Laura Oest Müllertz, Rasmus Michael Sandsdal, Simon Birk Kjaer Jensen, Signe Sørensen Torekov
Potent incretin-based therapy shows promise for the treatment of obesity along with reduced incidence of cardiovascular events in patients with preexisting cardiovascular disease and obesity. This study assessed the efficacy and safety of the incretin-based obesity treatments, once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg, in people with obesity without diabetes. Of the 744 records identified, seven randomized controlled trials (n = 5140) were included. Five studies (n = 3288) investigated semaglutide and two studies (n = 1852) investigated tirzepatide...
March 11, 2024: Obesity Reviews
https://read.qxmd.com/read/38461904/the-role-of-g-protein-coupled-receptor-kinases-in-glp-1r-%C3%AE-arrestin-recruitment-and-internalisation
#39
JOURNAL ARTICLE
Samantha M McNeill, Jessica Lu, Carlo Marion C Carino, Asuka Inoue, Peishen Zhao, Patrick M Sexton, Denise Wootten
The glucagon-like peptide 1 receptor (GLP-1R) is a validated clinical target for the treatment of type 2 diabetes and obesity. Unlike most G protein-coupled receptors (GPCRs), the GLP-1R undergoes an atypical mode of internalisation that does not require β-arrestins. While differences in GLP-1R trafficking and β-arrestin recruitment have been observed between clinically used GLP-1R agonists, the role of G protein-coupled receptor kinases (GRKs) in affecting these pathways has not been comprehensively assessed...
March 8, 2024: Biochemical Pharmacology
https://read.qxmd.com/read/38458647/glp-1-receptor-agonists-in-the-treatment-of-diabetic-non-alcoholic-steatohepatitis-patients
#40
JOURNAL ARTICLE
Ernest A Adeghate
INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is the most common hepatic disease affecting almost 30% of the world population. Approximately 25% of people with NAFLD develop nonalcoholic steatohepatitis (NASH), the fulminant version of the disease. Diabetes mellitus is present in 22.5% of people with NAFLD and 44.60% of individuals with NASH. This review was undertaken to examine the current contribution of glucagon-like peptide 1 (GLP-1) receptor agonists to the pharmacotherapy of diabetic nonalcoholic steatohepatitis...
March 8, 2024: Expert Opinion on Pharmacotherapy
keyword
keyword
79976
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.